From GlobeNewswire: 2025-05-19 16:01:00

Interim results from Alpha DaRT® trials for pancreatic cancer show >90% disease control rate and strong overall survival. A combination trial with Keytruda® in head and neck cancer demonstrates 75% systemic objective response rate. FDA approves pilot studies for Alpha DaRT in pancreatic and brain cancer, bolstering the Company’s capital position post-financing. MDSAP certification and completion of $36.9 million financing further enhance Alpha Tau’s progress in innovative cancer therapy development. Alpha Tau reports first quarter 2025 financial results and milestones achieved in evaluating Alpha DaRT for internal organ tumors. CEO Uzi Sofer highlights progress in clinical trials, manufacturing expansion, and upcoming commercial activities, including FDA approvals for U.S. pilot studies in pancreatic and brain cancer patients. Alpha Tau completes financing and strategic alliance with Oramed Pharmaceuticals, Inc., raising $36.9 million. IDE approval from FDA for Alpha DaRT pilot study in recurrent glioblastoma multiforme patients marks significant progress in cancer therapy development. Completion of MDSAP certification for manufacturing facility in Jerusalem enhances Alpha Tau’s regulatory compliance and potential for commercialization in key markets. FDA approval for U.S. pilot study of Alpha DaRT with chemotherapy in newly diagnosed pancreatic cancer patients signifies a step closer to regulatory approval and treatment advancement. Upcoming milestones include patient enrollment in pancreatic cancer pilot study and initiation of U.S. GBM pilot study. Alpha DaRT aims to provide potent alpha-irradiation to solid tumors, sparing healthy tissue. Alpha Tau, founded in 2016, focuses on developing and commercializing Alpha DaRT for cancer treatment. Alpha Tau’s financial results for Q1 2025 show increased R&D and G&A expenses, offset by financial income. The Company maintains a strong balance sheet with cash and equivalents totaling $54.8 million as of March 31, 2025.



Read more at GlobeNewswire:: Alpha Tau Announces First Quarter 2025 Financial Results